Topirva XR Capsule (Extended Release)

Introduction

Topirva XR Capsule (Extended Release) 50 mg is an anticonvulsant and antiepileptic drug used as a treatment for epilepsy as well as certain psychiatric disorders such as bipolar disorder and migraine headaches. It was approved for use in the United States by the FDA in 1996 and is prescribed either alone or in combination with other antiepileptic drugs such as Lamotrigine or Valproate

Uses for

The primary use of Topirva XR Capsule (Extended Release) 50 mg is as a treatment for epilepsy and as an adjunctive treatment for adults with partial onset seizures. It is also used as a preventive treatment for migraine and also for some psychiatric disorders such as bipolar disorder and bulimia nervosa.

Brand Name	Topirva XR
Type	Capsule (Extended Release)
Weight	50 mg
Generic	Topiramate
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Topirva XR Capsule (Extended Release) 50 mg works as an anticonvulsant by increasing the amount of gamma-aminobutyric acid (GABA) in the brain, which is a neurotransmitter that has a calming effect. It also blocks the action of glutamate, a neurotransmitter that has excitatory effects in the brain. This helps to reduce the amount of seizure activity.

How Long Does it Take to Work?

Topirva XR Capsule (Extended Release) 50 mg usually takes several weeks to improve seizures or other problems it is used to treat. It is important to take the medication as prescribed and not to stop taking it even if you don’t see immediate results.

Absorption

Topirva XR Capsule (Extended Release) 50 mg is absorbed quickly and completely when taken orally with food. It has a half-life of 19 hours and can reach peak concentrations in about two hours.

Route of Elimination

The main route of elimination for topiramate is through the urine. About 75% of a dose is excreted in the urine as topiramate and its metabolites, and the rest is excreted in the feces.

Dosage

Epilepsy: Monotherapy:

Adults and children over 16 years: Titration should begin at 25 mg nightly for 1 week. The dosage should then be increased at 1- or 2-week intervals by increments of 25 or 59 mg/day, administered in two divided doses. The recommended initial target dose for topiramate monotherapy in adults with newly diagnosed epilepsy is 100 mg/day and the maximum recommended daily dose is 400 mg.
Children aged 6-16 years: Treatment of children aged 6 years and above should begin at 0.5 to 1 mg/kg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 0.5 to 1 mg/kg/day, administered in two divided doses. The recommended initial target dose range for topiramate monotherapy in children with newly diagnosed epilepsy aged 6 years and above is 3 to 6 mg/kg/day. Higher doses have been tolerated and rarely doses up to 16 mg/kg/day have been given.

Epilepsy: Adjunctive therapy:

Adults and children over 16 years: The minimal effective dose as adjunctive therapy is 200 mg per day. The usual total daily dose is 200 mg to 400 mg in two divided doses. Some patients may require doses up to 800 mg per day, which is the maximum recommended dose.
Children aged 2-16 years: The recommended total daily dose of Topiramate as adjunctive therapy is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome. Daily doses up to 30 mg/kg/day have been studied and were generally well tolerated.

Migraine:

Adults and children over 16 years: Titration should begin at 25 mg nightly for 1-week. The dosage should then be increased in increments of 25 mg/day administered at 1-week intervals. The recommended total daily dose of topiramate as treatment for the prophylaxis of migraine headache is 100 mg/day administered in two divided doses. Some patients may experience a benefit at a total daily dose of 50 mg/day.
Children: Topiramate in migraine prophylaxis has not been studied in children under 16 years.

The typical dosage for adults for the treatment of epilepsy is 25 to 100mg twice daily. The dosage may be increased gradually up to 400mg per day in divided doses as needed. The maintenance dose is usually between 200 to 400mg per day.

Administration

Topirva XR Capsule (Extended Release) 50 mg can be taken orally with or without food. Tablets and sprinkle capsules are available for oral administration.

Side Effect

The most common side effect of topiramate is drowsiness. Other side effects include tiredness, nausea, diarrhea, weight loss, dizziness, memory problems, depression, anxiety, and difficulty concentrating. Less common side effects include tingling or numbness in extremities and changes in vision.

Toxicity

Topirva XR Capsule (Extended Release) 50 mg is generally well-tolerated, but in rare cases may cause serious side effects such as liver damage. It is important to contact your doctor right away if you experience any side effects while taking topiramate.

Precautions

People with a history of depression, kidney stones, or glaucoma should talk to their doctor before taking topiramate. The drug should not be taken by pregnant women, as it can cause birth defects. Before taking topiramate, it is important to discuss any medical conditions or allergies with your doctor.

Interaction

Topirva XR Capsule (Extended Release) 50 mg may interact with other drugs. It is important to inform your doctor of any medications you are taking, as well as any vitamins, herbal supplements, or over-the-counter drugs you are taking. Some drugs may increase or decrease the effectiveness of topiramate, and some drugs may cause serious adverse reactions. It is important to talk to your doctor before starting any new medications while taking topiramate.

Disease Interaction

People with certain diseases or conditions may need to adjust their dosage of topiramate, as the drug can interact with some medical conditions. These include but are not limited to kidney disease, liver disease, bipolar disorder, glaucoma, depression, obesity, and diabetes.

Drug Interaction

Topirva XR Capsule (Extended Release) 50 mg can interact with other drugs, some of which may increase or decrease the effects of the drug. It is important to discuss any other medications you are taking with your doctor, as some drugs may interact with topiramate and cause serious side effects. These drugs include but are not limited to anticonvulsants, birth control pills, certain antibiotics, and antifungal medications.

Food Interaction

Foods containing calcium, iron, or magnesium can reduce the absorption of topiramate, so it is important to take topiramate at least two hours before or after consuming these substances. It is also important to avoid taking topiramate with alcohol, as this may increase the side effects.

Pregnancy Use

Topirva XR Capsule (Extended Release) 50 mg should not be taken during pregnancy as it can cause birth defects. Women who become pregnant while taking topiramate should contact their doctor immediately.

Lactation Use

It is not recommended to take topiramate while breastfeeding due to the risk of passing the drug to the baby in the milk.

Acute Overdose

The symptoms of an acute overdose of topiramate include confusion, drowsiness, and slowed, shallow breathing. If you or someone you know has taken too much topiramate, contact a doctor or poison control center right away.

Contraindication

Topirva XR Capsule (Extended Release) 50 mg is contraindicated in people with a history of kidney stones, glaucoma, and certain allergies. It is also contraindicated in pregnant women and breastfeeding mothers.

Use Direction

Topirva XR Capsule (Extended Release) 50 mg should be taken exactly as prescribed by your doctor. Do not take more or less than the recommended dose, and do not stop taking the medication without first consulting your doctor.

Storage Condition

Topirva XR Capsule (Extended Release) 50 mg should be stored at room temperature, in a light-resistant container. Store away from heat, moisture, and direct sunlight.